Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Short term Debt (2016 - 2022)

Aptevo Therapeutics (APVO) has disclosed Short term Debt for 8 consecutive years, with $2.0 million as the latest value for Q4 2022.

  • Quarterly Short term Debt fell 82.86% to $2.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2022, down 82.86% year-over-year, with the annual reading at $2.0 million for FY2022, 82.86% down from the prior year.
  • Short term Debt hit $2.0 million in Q4 2022 for Aptevo Therapeutics, roughly flat from $2.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $19.9 million in Q4 2019 to a low of $2.0 million in Q1 2022.
  • Historically, Short term Debt has averaged $8.1 million across 5 years, with a median of $5.3 million in 2018.
  • Biggest five-year swings in Short term Debt: soared 133.34% in 2021 and later tumbled 82.86% in 2022.
  • Year by year, Short term Debt stood at $4.2 million in 2018, then soared by 376.67% to $19.9 million in 2019, then plummeted by 74.83% to $5.0 million in 2020, then skyrocketed by 133.34% to $11.7 million in 2021, then crashed by 82.86% to $2.0 million in 2022.
  • Business Quant data shows Short term Debt for APVO at $2.0 million in Q4 2022, $2.0 million in Q3 2022, and $2.0 million in Q2 2022.